I asked about the distribution of numbers on the investor hub, as I was also thinking 22 was 1 shy of full recruitment and completion of both phase 1 and 2. (going by my understanding of details in original announcements).
Response received indicates there was as expansion stage to phase 1 (separate to Phase 2), which in original announcement does say up to 12 patients. So from response, numbers provided where 13 in phase 1 ( 6 dose escalation 7 in expansion), then 7 recruited for the stage 1 of the phase 2, for total of 22 patients.
Ann: Zantrene AML trial in Israel advances to Phase 2, page-143
-
- There are more pages in this discussion • 91 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
0.040(2.86%) |
Mkt cap ! $245.3M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.49 | $1.41 | $101.7K | 69.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9216 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 7767 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |